Type 2 diabetes, cardiovascular risk, and the link to insulin resistance

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Patient with Type 2 Diabetes 100%
• Cardiovascular Risk 100%
• Insulin Resistance 100%
• Hyperglycemia 75%
• Thiazolidinedione 75%
• Cardiovascular System 75%
• Hypertension 75%
• Diabetes 50%
• Dyslipidemia 50%
• Microalbuminuria 50%
• Macrovascular Disease 50%
• Microangiopathy 50%
• Health Outcomes 25%
• Rosiglitazone 25%
• Blood Pressure 25%
• Cardiovascular Disease 25%
• Myocardial Infarction 25%
• Sequela 25%
• Edema 25%
• Pioglitazone 25%
• Risk Reduction 25%
• Metabolic Syndrome 25%
• Vasculitis 25%
• C Reactive Protein 25%
• Fibrinolysis 25%
• Retinopathy 25%
• Liver Toxicity 25%
• Insulin Sensitizing Agent 25%
• Apoplexy 25%
• Atherosclerosis 25%
• Inflammation 25%
• Hemodynamic 25%
• Plasminogen Activator Inhibitor-1 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Cardiovascular Risk 100%
• Insulin Resistance 100%
• Maturity Onset Diabetes of the Young 100%
• Thiazolidinedione 50%
• Hyperglycemia 50%
• Hypertension 50%
• Microalbuminuria 33%
• Dyslipidemia 33%
• Diseases 33%
• Hepatotoxicity 16%
• Atherosclerosis 16%
• Heart Infarction 16%
• Metabolic Syndrome X 16%
• Pioglitazone 16%
• Rosiglitazone 16%
• C Reactive Protein 16%
• Cerebrovascular Accident 16%
• Inflammation 16%
• Edema 16%
• Cardiovascular Disease 16%
• Insulin Sensitizing Agent 16%
• Retinopathy 16%
• Vasculitis 16%
• Plasminogen Activator Inhibitor 1 16%

Nursing and Health Professions

• Microalbuminuria 50%